While promising, they should not replace grading dysplasia for risk stratification in routine clinical practice at this time (68). Conclusions DNA Methyltransferase inhibitor Although newer techniques are being studied, at this time none have definitively been shown to be more cost effective than careful clinical evaluations and systematic biopsy screening. Good patient care includes coordination of careful microscopic study with patient

clinical history. The findings of both the endoscopist and the pathologist are critical. Acknowledgements Disclosure: The authors declare no conflict of interest.
The gastrointestinal (GI) tract is an anatomic term used to denote Inhibitors,research,lifescience,medical the tubular digestive system and its accessory organs. It is often divided into the upper GI tract, Inhibitors,research,lifescience,medical lower GI tract, and accessory organs for

purposes of discussing its diseases. The upper GI tract consists of the esophagus, stomach, and duodenum, whereas the lower GI tract comprises the remainder of the small intestine, the colon, and the anus. The accessory organs include the liver, gallbladder, pancreas, and the hepatobiliary and pancreatic ducts. Although any portion of the GI tract may develop malignancy, Inhibitors,research,lifescience,medical the esophagus, stomach, and colon (including rectum) are the most common. In fact, esophagogastric and colorectal carcinomas are among the most frequently occurring deadly diseases in humans worldwide. Other commonly encountered GI primary tumors include lymphoproliferative Inhibitors,research,lifescience,medical disorders, hepatocellular carcinoma, and neuroendocrine and mesenchymal tumors (including GI stromal tumors). The pathogenesis and etiology of GI tumors is typically multi-factorial, varies with the

specific tumor type, and may involve environmental factors (dietary, Inhibitors,research,lifescience,medical low socioeconomic status, cigarette smoking, alcohol use, nutritional deficiencies), host factors (certain precancerous conditions), infection (human papillomavirus, helicobacter pylori), and underlying genetic susceptibility. In the emerging era of personalized medicine, the pathologist’s role in the management of patients with GI malignancies has been greatly Nutlin-3a order expanded from that of simply a traditional histomorphologist, to an active clinical consultant for gastroenterologists, surgeons, oncologists and medical geneticists, as well as patients. Today, the pathologist not only needs to provide an accurate histopathologic diagnosis, but is also responsible for accurately defining pathologic stage, evaluating surgical margins, assessing the efficacy of various neoadjuvant therapeutic modalities, and identifying the presence or absence of various relevant prognostic parameters and therapeutic targets.